SCHEMBL5437206

SCHEMBL5437206

COc1cc(Cl)cc(N=C=O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.40
MAPK1 P28482 1/20 0.40
ALDH1A1 P00352 3/20 0.36
HPGD P15428 2/20 0.36
CYP3A4 P08684 2/20 0.36
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
PKM P14618 1/20 0.35
ALOX12 P18054 1/20 0.35
MPI P34949 1/20 0.35
HTT P42858 1/20 0.35
CACNA1B Q00975 1/20 0.35
APBA1 Q02410 1/20 0.35
TRPA1 O75762 1/20 0.34
MAPT P10636 1/20 0.34
MARS1 P56192 1/20 0.33
AHR P35869 1/20 0.33
GSK3B P49841 2/20 0.33
FFAR4 Q5NUL3 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL135276 0.86 ALDH1A1 (0.50) TDP1MAPK1ALDH1A1HPGDCYP3A4
SCHEMBL3896348 0.86 ALDH1A1 (0.43) TDP1MAPK1ALDH1A1HPGDCYP3A4
SCHEMBL10316610 0.80 MAPK1 (0.52) TDP1MAPK1CYP3A4TRPA1ERN1
SCHEMBL93410 0.80 MAPK1 (0.52) TDP1MAPK1CYP3A4TRPA1ERN1
SCHEMBL14088888 0.79 ALDH1A1 (0.40) ALDH1A1HPGDCYP3A4KMT2AKDM4E
SCHEMBL29556081 0.78 CYP3A4 (0.36) TDP1MAPK1ALDH1A1HPGDCYP3A4
SCHEMBL28202222 0.78 MAPK1 (0.50) TDP1MAPK1CYP3A4TRPA1ERN1
SCHEMBL30235537 0.77 HDAC3 (0.41) TDP1MAPK1MPIFFAR4P2RX1
SCHEMBL18423003 0.77 HDAC3 (0.41) TDP1MAPK1MPIFFAR4P2RX1
SCHEMBL7530889 0.75 CYP1A2 (0.47) TDP1ALDH1A1HPGDCYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459925-B2 Sulphonyl urea derivatives as NLRP3 inflammasome modulators NodThera Limited (GB) 2025-11-04 US disclosed
EP-3728238-B1 SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS NODTHERA LTD (GB) 2025-06-18 EP disclosed
US-20240368129-A1 SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS NodThera Limited (GB) 2024-11-07 US disclosed
US-12012397-B2 Sulphonyl urea derivatives as NLRP3 inflammasome modulators NodThera Limited (GB) 2024-06-18 US disclosed
EP-4121415-B1 INHIBITORS OF CYTOKININ OXIDASE DERIVED FROM 1-[2-(HYDROXYALKYL)PHENYL]-3-YLUREA, USE THEREOF AND PREPARATIONS CONTAINING THESE DERIVATIVES UNIV PALACKEHO (CZ) 2024-02-07 EP disclosed
US-20230145050-A1 SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS NodThera Limited (GB) 2023-05-11 US disclosed
EP-4121415-A1 INHIBITORS OF CYTOKININ OXIDASE DERIVED FROM 1-[2-(HYDROXYALKYL)PHENYL]-3-YLUREA, USE THEREOF AND PREPARATIONS CONTAINING THESE DERIVATIVES Univerzita Palackého v Olomouci (CZ) 2023-01-25 EP disclosed
US-11518757-B2 Sulphonyl urea derivatives as NLRP3 inflammasome modulators NodThera Limited (GB) 2022-12-06 US disclosed
WO-2021185391-A1 INHIBITORS OF CYTOKININ OXIDASE DERIVED FROM 1-[2-(HYDROXYALKYL)PHENYL]-3-YLUREA, USE THEREOF AND PREPARATIONS CONTAINING THESE DERIVATIVES UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2021-09-23 WO disclosed
US-20210002261-A1 SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS NodThera Limited (GB) 2021-01-07 US disclosed
CN-111954670-A Sulfonylurea derivatives as NLRP3 inflammasome modulators 诺瑟拉有限公司 2020-11-17 CN disclosed
EP-3728238-A1 SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS Nodthera Limited (GB) 2020-10-28 EP disclosed
US-20070191353-A1 Use of thiadiazoleurea derivatives MERCK PATENT GMBH (DE) 2007-08-16 US disclosed
EP-1720846-A1 USE OF THIADIAZOLE UREA DERIVATIVES MERCK PATENT GmbH (DE) 2006-11-15 EP disclosed
WO-2005085220-A1 USE OF THIADIAZOLE UREA DERIVATIVES MERCK PATENT GMBH (DE) 2005-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12012397-B2 Sulphonyl urea derivatives as NLRP3 inflammasome modulators NLRP3, NOD1, IL1B TDP1 976/4885MAPK1 489/4885ALDH1A1 612/4885
US-20230145050-A1 SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS NLRP3, NOD1, IL1B TDP1 976/4885MAPK1 489/4885ALDH1A1 612/4885
US-20240368129-A1 SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS NLRP3, NOD1, IL1B TDP1 976/4885MAPK1 489/4885ALDH1A1 612/4885
US-11518757-B2 Sulphonyl urea derivatives as NLRP3 inflammasome modulators NLRP3, NOD1, IL1B TDP1 976/4885MAPK1 489/4885ALDH1A1 612/4885
US-20210002261-A1 SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS NLRP3, NOD1, IL1B TDP1 976/4885MAPK1 489/4885ALDH1A1 612/4885
US-12459925-B2 Sulphonyl urea derivatives as NLRP3 inflammasome modulators NLRP3, NOD1, IL1B TDP1 976/4885MAPK1 489/4885ALDH1A1 612/4885
US-20070191353-A1 Use of thiadiazoleurea derivatives RAF1, ARAF, JAK1 TDP1 1417/4885MAPK1 10/4885ALDH1A1 721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.